These are manufactured by major pharmaceutical companies and are typically dispensed through traditional retail pharmacies
Although both medications boast tirzepatide as their active ingredient, their purposes differ significantly
Because a single vial covers several weekly doses, a repeated one- or two-unit error compounds across the whole vials life
fast Download PDF Now- 20262029 pipeline snapshot: Novo Nordisk CagriSema (GLP-1 + amylin) Filing 2026 Lilly Orforglipron (oral GLP-1) + Retatrutide (triple agonist) Launch window 20262027 Amgen Maritide (GLP-1 + GIP) 20272028 target BI / Zealand Survodutide (GLP-1 + glucagon) 2027 Altimmune Pemvidutide (GLP-1 + glucagon) 2027 Roche CT-388 / Petrelintide possible 2029 And one notable miss: Pfizer Danuglipron discontinued Clear trend: Single GLP-1 dual triple agonists Competition is shifting from: Who has a GLP-1? to Who has the most effective combination biology? Execution risk is still real but the bar for efficacy is moving quickly
References: Bonaldi, Lorenza & Mascolini, Maria & Todesco, Martina & Zara, Anna & Rossato, Camilla & Fede, Caterina & Fontanella, chiara giulia & Stecco, Carla
